Article

Endoscopic cardiac tumor resection.

Department of Cardiovascular and Thoracic Surgery, OLV Clinic, Aalst, Belgium.
The Annals of thoracic surgery (Impact Factor: 3.45). 07/2007; 83(6):2142-6. DOI: 10.1016/j.athoracsur.2007.01.064
Source: PubMed

ABSTRACT The purpose of this study is to report our 9 years' experience with endoscopic cardiac tumor resection using the port access approach.
From March 1997 to December 2005, 27 patients (mean age, 56.2 +/- 16.9 years; 70% female) underwent endoscopic cardiac tumor resection using endocardiopulmonary bypass and endoaortic-balloon clamp technique. Nineteen (70%) patients presented in New York Heart Association class I, 4 patients presented with embolic stroke, and 4 patients presented with atrial arrhythmias. All patients underwent echocardiography on admission, intraoperatively, at discharge, and at follow-up evaluation. Eight patients additionally required mitral valve replacement (n = 1), tricuspid valve replacement (n = 1), mitral valve repair (n = 2), mini-maze (n = 1), and closure of patent foramen ovale (n = 3). Mean follow-up was 3.4 +/- 2.7 years.
Mean endoaortic-balloon clamp and endocardiopulmonary bypass times were 68.8 +/- 30.8 minutes and 112.2 +/- 41.5 minutes, respectively. There were no conversions to sternotomy. Tumors resected were classified as left atrial myxoma (n = 20), right atrial myxoma (n = 3), lipoma (n = 1), intravenous leiomyoma involving the inferior vena cava and the tricuspid valve (n = 1), plexiform tumor of the sinoatrial node (n = 1), and papillary fibroelastoma of aortic valve noncoronary cusp (n = 1). There were no hospital deaths. Mean intensive care unit and hospital stays were 1.4 +/- 1.1 days and 7.3 +/- 3.4 days, respectively. Postoperative complications were evolving stroke (n = 1), re-exploration for bleeding (n = 1), and myocardial ischemia requiring stenting (n = 1). Follow-up failed to demonstrate residual or recurrent tumor. One patient had a small residual atrial septal defect. Ninety-two percent of patients appreciated the cosmetic result and fast recovery.
Endoscopic cardiac tumor resection is feasible and a valid oncologic approach with an attractive cosmetic advantage over median sternotomy.

0 Bookmarks
 · 
139 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Advances in optics and instrumentation with the da Vinci S Surgical System have facilitated minimally invasive and robotic cardiac procedures including mitral valve repair and atrial myxoma excision. We report our retrospective data comparing robotically assisted myxoma excision with standard median sternotomy excision. Data were collected for cardiac myxoma resection performed between January 2000 and December 2009. The resulting cohort included a total of 57 patients. These patients were grouped into two categories: robotic-assisted (n = 17) surgical procedures and traditional (nonrobotic; n = 40) surgical procedures. Presurgical and surgical risk factors were examined. Univariate analysis comparing the surgical procedure groups and surgical risk factors found a significant difference in 3 of the 14 variables. Cannulation in all patients undergoing robotic-assisted cardiac myxoma excision was performed through cannulating the common femoral artery and vein while cannulation for the traditional procedures was performed using the aorta and atrium except for two patients. For aortic occlusion, 14 of the robotic-assisted cardiac myxoma patients had balloon occlusion and 34 of the traditional cardiac myxoma patients had aortic cross-clamp occlusion. Operating time was significantly shorter for robotic cases (2.7 hours) compared with traditional cases (3.5 hours). Robotic excision of atrial myxomas is safe and may be an alternative to traditional open surgery in selected patients.
    Journal of Cardiac Surgery 05/2012; 27(4):423-6. · 1.35 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: An asymptomatic 57-year-old woman presented for resection of a fifth cardiac myxoma. To avoid complete redissection of the heart, we proposed a video-assisted transaortic approach for a recurrent left ventricle (LV) myxoma resection. In a hybrid approach, sternotomy and open aortotomy provided the minimally invasive transaortic access to the myxoma. The myxoma was discovered during a routine echocardiographic screening. A 30° 5-mm scope, video-assisted thoracic surgery graspers, and endoshears were used for resection. The video-assisted technique significantly enhanced the intracardiac visualization, and a smaller, second myxoma was discovered after resection of the primary lesion. Both myxoma beds were additionally ablated to prevent recurrence. The total video-assisted operating time was 58 minutes. The transaortic valve approach avoided an atriotomy or ventriculotomy in a fifth redo operation. A transaortic valve approach to LV intracardiac lesions is safe and feasible, and it provides excellent visibility for complex cardiac cases.
    The Annals of thoracic surgery 01/2013; 95(1):340-2. · 3.45 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Cardiac tumors are assumed to be a rare entity. Metastases to the heart are more frequent than primary lesions. Sarcomas make up the majority of cardiac malignant neoplasms. Among them angiosarcoma is the most common and associated with the worst prognosis. Malignant fibrous histiocytoma comprises the minority of cardiac sarcomas and has uncertain etiology as well as pathogenesis. Transthoracic echocardiography remains the widely available screening examination for the initial diagnosis of a cardiac tumor. The clinical presentation is non-specific and the diagnosis is established usually at an advanced stage of the disease. Sarcomas spread preferentially through blood due to their immature vessels without endothelial lining. Surgery remains the method of choice for treatment. Radicalness of the excision is still the most valuable prognostic factor. Adjuvant therapy is unlikely to be effective. The management of cardiac sarcomas must be individualized due to their rarity and significant differences in the course of disease.
    Archives of Medical Science 02/2014; 10(1):135-48. · 1.89 Impact Factor

Full-text (2 Sources)

View
27 Downloads
Available from
May 30, 2014